ExploreWatchlistsPricing
  1. US-listed companies
  2. IMMUNIC, INC.
  3. Financials
  4. Research & development

IMMUNIC, INC. (IMUX)

Market cap
$1.3B
P/E ratio
SummaryFinancials
Period EndResearch & development (Million USD)YoY (%)
Dec 31, 202582+2.42%
Dec 31, 202480-3.81%
Dec 31, 202383+16.78%
Dec 31, 202271+16.59%
Dec 31, 202161+58.18%
Dec 31, 202039+71.63%
Dec 31, 201923-9.32%
Dec 31, 201825-36.90%
Dec 31, 201739+30.94%
Dec 31, 201630-24.46%
Dec 31, 201540+0.74%
Dec 31, 201439

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat